

Caroline M Moore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7216932/publications.pdf>

Version: 2024-02-01

197
papers

9,915
citations

71004

43
h-index

45040

94
g-index

203
all docs

203
docs citations

203
times ranked

8080
citing authors

#	ARTICLE	IF	CITATIONS
1	Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Courtsoyiannis teaching fellowship. <i>European Radiology</i> , 2023, 33, 461-471.	2.3	13
2	Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial. <i>European Radiology</i> , 2022, 32, 879-889.	2.3	32
3	Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease?. <i>British Journal of Radiology</i> , 2022, 95, 20210321.	1.0	5
4	Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score. <i>British Journal of Radiology</i> , 2022, 95, 20210415.	1.0	22
5	Knowledge and insights from a maturing international clinical quality registry. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 964-969.	2.2	1
6	Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data. <i>European Urology Open Science</i> , 2022, 36, 1-8.	0.2	13
7	Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study. <i>Diagnostics</i> , 2022, 12, 231.	1.3	5
8	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.2	13
9	Active Surveillance for Prostate Cancer: Will Magnetic Resonance Imaging Help Us Address the Current Controversies in Traditional Surveillance Approaches?. <i>European Urology</i> , 2022, 81, 347-348.	0.9	1
10	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. <i>European Urology</i> , 2022, 81, 407-413.	0.9	41
11	A protocol for the VISION study: An individual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultrasound guided biopsy in the detection of prostate cancer. <i>PLoS ONE</i> , 2022, 17, e0263345.	1.1	2
12	There Is No Longer a Role for Systematic Biopsies in Prostate Cancer Diagnosis. <i>European Urology Open Science</i> , 2022, 38, 12-13.	0.2	8
13	The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.. <i>PLoS ONE</i> , 2022, 17, e0259672.	1.1	2
14	Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. <i>European Urology</i> , 2022, 81, 598-605.	0.9	9
15	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. <i>Prostate</i> , 2022, 82, 876-879.	1.2	2
16	The Global Reading Room: MRI-Targeted Prostate Biopsy After Proctocolectomy. <i>American Journal of Roentgenology</i> , 2022, 219, 842-843.	1.0	2
17	Magnetic Resonance Imaging-guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies. <i>European Urology Open Science</i> , 2022, 38, 40-43.	0.2	5
18	Histo-MRI map study protocol: a prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer. <i>BMJ Open</i> , 2022, 12, e059847.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Geographic Variability, Time Trends and Association of Preoperative Magnetic Resonance Imaging with Surgical Outcomes for Elderly United States Men with Prostate Cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Journal of Urology</i> , 2022, 208, 609-617.	0.2	6
20	Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models. <i>Diagnostics</i> , 2022, 12, 1631.	1.3	0
21	The mpMRI Enough-or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy. <i>European Urology Focus</i> , 2021, 7, 1027-1034.	1.6	17
22	Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy. <i>European Urology Focus</i> , 2021, 7, 1300-1307.	1.6	44
23	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021, 127, 96-107.	1.3	15
24	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. <i>World Journal of Urology</i> , 2021, 39, 1115-1119.	1.2	23
25	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. <i>European Urology Focus</i> , 2021, 7, 102-110.	1.6	28
26	Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations. <i>American Journal of Roentgenology</i> , 2021, 216, 943-951.	1.0	18
27	Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. <i>European Radiology</i> , 2021, 31, 1644-1655.	2.3	37
28	The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 370-395.	2.6	25
29	PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 216, 3-19.	1.0	76
30	Role of MRI for the detection of prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 637-649.	1.2	6
31	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 567-574.	2.0	28
32	Mixed acinar and macrocystic ductal prostatic adenocarcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e37.	5.1	1
33	Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 612-622.	2.0	6
34	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021, 21, 18.	0.6	3
35	Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 868-876.	2.6	72
36	Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?. <i>Journal of Urology</i> , 2021, 205, 740-747.	0.2	13

#	ARTICLE	IF	CITATIONS
37	A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. <i>European Urology</i> , 2021, 79, 325-326.	0.9	44
38	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. <i>Cancers</i> , 2021, 13, 1985.	1.7	10
39	The Importance of Being PRECISE in Prostate Magnetic Resonance Imaging and Active Surveillance. <i>European Urology</i> , 2021, 79, 560-563.	0.9	7
40	Letâ€™s Follow the Golden Mean: Using Magnetic Resonance Imaging to Determine the Need for Biopsy in Men on Active Surveillance. <i>European Urology Oncology</i> , 2021, 4, 235-236.	2.6	1
41	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Letter.. <i>Journal of Urology</i> , 2021, 205, 1233-1234.	0.2	0
42	Morphological Change Forecasting For Prostate Glands Using Feature-Based Registration And Kernel Density Extrapolation. , 2021, , .		1
43	Comparison of Multiparametric Magnetic Resonance Imagingâ€™Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 534.	3.4	99
44	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.. <i>Journal of Urology</i> , 2021, 205, 1526-1528.	0.2	0
45	Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. <i>Insights Into Imaging</i> , 2021, 12, 59.	1.6	43
46	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1120-1128.	2.0	10
47	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1028-1031.	2.0	10
48	Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 830.e1-830.e8.	0.8	5
49	Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging. <i>European Urology Focus</i> , 2021, 7, 503-505.	1.6	5
50	Outcomes of the RAFT trial: robotic surgery after focal therapy. <i>BJU International</i> , 2021, 128, 504-510.	1.3	8
51	MRI Targeted Prostate Biopsy Techniques: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 217, 1263-1281.	1.0	7
52	Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study. <i>European Urology Open Science</i> , 2021, 30, 16-24.	0.2	4
53	ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. <i>BMJ Open</i> , 2021, 11, e048144.	0.8	10
54	An important step towards smarter screening for prostate cancer. <i>Lancet Oncology</i> , The, 2021, 22, 1201-1202.	5.1	1

#	ARTICLE	IF	CITATIONS
55	Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090.	6.3	240
56	Multiparametric prostate MRI quality assessment using a semi-automated PI-QUAL software program. <i>European Radiology Experimental</i> , 2021, 5, 48.	1.7	17
57	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. <i>Nature Reviews Urology</i> , 2020, 17, 41-61.	1.9	207
58	Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial. <i>BJU International</i> , 2020, 125, 391-398.	1.3	8
59	Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study. <i>European Radiology</i> , 2020, 30, 2082-2090.	2.3	20
60	Magnetic Resonance Imaging Should Be Used in the Active Surveillance of Patients with Localised Prostate Cancer. <i>European Urology</i> , 2020, 77, 318-319.	0.9	10
61	DWI and PRECISE criteria in men on active surveillance for prostate cancer: A multicentre preliminary experience of different ADC calculations. <i>Magnetic Resonance Imaging</i> , 2020, 67, 50-58.	1.0	14
62	Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. <i>European Urology Oncology</i> , 2020, 3, 615-619.	2.6	155
63	Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. <i>Eur Urol</i> 2020;77:501-7. <i>European Urology</i> , 2020, 78, e106-e107.	0.9	1
64	Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll's Letter to the Editor re: Vasilis Stavriniades, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443-51. <i>European Urology</i> , 2020, 78, e112-e113.	0.9	0
65	Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavriniades, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>Eur Urol</i> 2020;78:443-51. <i>European Urology</i> , 2020, 78, e166.	0.9	0
66	Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE. <i>British Journal of Radiology</i> , 2020, 93, 20200819.	1.0	11
67	Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype. <i>Communications Biology</i> , 2020, 3, 440.	2.0	4
68	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. <i>European Urology</i> , 2020, 78, 155-160.	0.9	18
69	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. <i>European Urology Oncology</i> , 2020, 3, 145-167.	2.6	75
70	A feasibility study of a psychoeducational support intervention for men with prostate cancer on active surveillance. <i>Cancer Reports</i> , 2020, 3, e1230.	0.6	2
71	Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. <i>BJU International</i> , 2020, 125, 853-860.	1.3	23
72	Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>European Urology</i> , 2020, 78, 443-451.	0.9	94

#	ARTICLE	IF	CITATIONS
73	Prostate-specific membrane antigen PET-CT before radical treatment. <i>Lancet</i> , 2020, 395, 1170-1172.	6.3	5
74	An Exploratory Study of Dose Escalation vs Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , 2020, 34, 641-646.	1.1	7
75	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 78, 402-414.	0.9	183
76	Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. <i>Journal of Urology</i> , 2020, 203, 734-742.	0.2	33
77	The role of additional standard biopsy in the MRI-targeted biopsy era. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 637-639.	3.9	12
78	Mycobacterial immunotherapy for prostate cancer: where can we go from here?. <i>Nature Reviews Urology</i> , 2020, 17, 189-190.	1.9	2
79	Assessment of a patient-reported outcome measure in men with prostate cancer who had radical surgery: a Rasch analysis. <i>BMJ Open</i> , 2020, 10, e035436.	0.8	0
80	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1065-1066.	0.2	0
81	Assessment of a patient-reported outcome measure in men with prostate cancer who had radical surgery: a Rasch analysis. <i>BMJ Open</i> , 2020, 10, e035436.	0.8	0
82	Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches. <i>World Journal of Urology</i> , 2019, 37, 419-427.	1.2	9
83	MRI in active surveillance: a critical review. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 5-15.	2.0	36
84	Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. <i>Eur Urol</i> 2019;76:284-303. <i>European Urology</i> , 2019, 76, e133-e134.	0.9	0
85	Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. <i>PLoS ONE</i> , 2019, 14, e0221350.	1.1	13
86	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	0.9	18
87	Automatic segmentation of prostate MRI using convolutional neural networks: Investigating the impact of network architecture on the accuracy of volume measurement and MRI-ultrasound registration. <i>Medical Image Analysis</i> , 2019, 58, 101558.	7.0	45
88	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 284-303.	0.9	153
89	The Evolution of MRI of the Prostate: The Past, the Present, and the Future. <i>American Journal of Roentgenology</i> , 2019, 213, 384-396.	1.0	39
90	Role of MRI in planning radical prostatectomy: what is the added value?. <i>World Journal of Urology</i> , 2019, 37, 1289-1292.	1.2	26

#	ARTICLE	IF	CITATIONS
91	Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. <i>European Urology</i> , 2019, 76, 27-30.	0.9	53
92	VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. <i>Radiology</i> , 2019, 291, 391-397.	3.6	52
93	Best practice in active surveillance for men with prostate cancer: a Prostate Cancer <sc>UK</sc> consensus statement. <i>BJU International</i> , 2019, 124, 47-54.	1.3	23
94	Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome. <i>Magnetic Resonance Imaging</i> , 2019, 58, 143-147.	1.0	13
95	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. <i>BJU International</i> , 2019, 124, 431-440.	1.3	93
96	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019, 2, 333-336.	2.6	8
97	MRI in early detection of prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 563-568.	0.9	8
98	Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program. <i>Magnetic Resonance Imaging</i> , 2019, 57, 34-39.	1.0	13
99	A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI. <i>European Urology</i> , 2019, 75, 203-204.	0.9	16
100	Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging. <i>European Radiology</i> , 2019, 29, 3159-3169.	2.3	34
101	The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. <i>European Urology</i> , 2019, 75, 733-740.	0.9	67
102	Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 261-267.	2.0	9
103	Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. <i>Journal of Urology</i> , 2019, 201, 1134-1143.	0.2	19
104	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 928-928.	0.2	0
105	Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasound-guided prostate interventions. <i>Medical Physics</i> , 2018, 45, 1408-1414.	1.6	7
106	Can Negative Prostate Magnetic Resonance Imaging Give Us the Reassurance We Need To Avoid Standard Biopsy? An Evidence-based Practical Approach. <i>European Urology</i> , 2018, 74, 55-56.	0.9	4
107	Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis. <i>BJU International</i> , 2018, 122, 946-958.	1.3	73
108	A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 67-76.	0.8	19

#	ARTICLE	IF	CITATIONS
109	Centralising specialist cancer surgery services in England: survey of factors that matter to patients and carers and health professionals. <i>BMC Cancer</i> , 2018, 18, 226.	1.1	21
110	National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection – recommendations from a UK consensus meeting. <i>BJU International</i> , 2018, 122, 13-25.	1.3	106
111	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018, 378, 1767-1777.	13.9	2,036
112	Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 13.e1-13.e10.	0.8	11
113	Prostate cancer detection using quantitative T ₂ and T ₂ -weighted imaging: The effects of 5 α -reductase inhibitors in men on active surveillance. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1646-1653.	1.9	12
114	Magnetic resonance imaging in active surveillance – a modern approach. <i>Translational Andrology and Urology</i> , 2018, 7, 116-131.	0.6	11
115	A picture is worth a thousand words – but does it add utility to a nomogram to predict extraprostatic extension?. <i>BJU International</i> , 2018, 122, 915-916.	1.3	0
116	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. <i>BMJ Open</i> , 2018, 8, e024941.	0.8	14
117	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 1121-1121.	0.2	0
118	Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study. <i>Journal of Urology</i> , 2018, 200, 1235-1240.	0.2	55
119	Label-driven weakly-supervised learning for multimodal deformable image registration. , 2018, , .		67
120	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 422-429.	0.9	220
121	“Don’t Let the Perfect Be the Enemy of the Good”: Time to Embrace Magnetic Resonance Imaging Before First Prostate Biopsy. <i>European Urology</i> , 2018, 74, 411-412.	0.9	2
122	Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates. <i>Prostate</i> , 2018, 78, 1229-1237.	1.2	9
123	The natural history of prostate cancer on MRI: lessons from an active surveillance cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 556-563.	2.0	13
124	Weakly-supervised convolutional neural networks for multimodal image registration. <i>Medical Image Analysis</i> , 2018, 49, 1-13.	7.0	280
125	Accuracy of Transperineal Targeted Prostate Biopsies, Visual Estimation and Image Fusion in Men Needing Repeat Biopsy in the PICTURE Trial. <i>Journal of Urology</i> , 2018, 200, 1227-1234.	0.2	38
126	MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 473-487.	2.0	42

#	ARTICLE	IF	CITATIONS
127	MRI-Targeted Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018, 379, 589-590.	13.9	59
128	Integration of spatial information in convolutional neural networks for automatic segmentation of intraoperative transrectal ultrasound images. <i>Journal of Medical Imaging</i> , 2018, 6, 1.	0.8	23
129	Can MRI Replace Biopsy in Men on Surveillance?. <i>Current Clinical Urology</i> , 2018, , 111-119.	0.0	0
130	Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 946-958.	2.5	14
131	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendationsâ€”A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 648-655.	0.9	190
132	Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An inÂvitro study in 2D and 3D prostate cancer models. <i>Cancer Letters</i> , 2017, 393, 68-75.	3.2	22
133	Focal salvage highâ€”intensity focused ultrasound in radiorecurrent prostate cancer. <i>BJU International</i> , 2017, 120, 246-256.	1.3	39
134	PD55-01 DUTASTERIDE AND ACTIVE SURVEILLANCE IN PROSTATE CANCER: ARE VISIBLE LESIONS LESS CONSPICUOUS AT MAGNETIC RESONANCE IMAGING? A PILOT RANDOMIZED CONTROLLED TRIAL. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
135	Role of MRI in low-risk prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 238-245.	0.9	15
136	Patientâ€”reported outcome (<scp>PRO</scp>) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments. <i>BJU International</i> , 2017, 120, 468-481.	1.3	29
137	The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. <i>British Journal of Cancer</i> , 2017, 116, 1159-1165.	2.9	90
138	Semantics in active surveillance for men with localized prostate cancer â€” results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017, 14, 312-322.	1.9	65
139	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. <i>BMJ Open</i> , 2017, 7, e017863.	0.8	14
140	Intraoperative Organ Motion Models with an Ensemble of Conditional Generative Adversarial Networks. <i>Lecture Notes in Computer Science</i> , 2017, , 368-376.	1.0	8
141	PD65-10 USING MP-MRI GUIDED PROSTATE NEEDLE BIOPSY SAMPLES TO IMPROVE PROSTATE CANCER DIAGNOSIS.. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
142	MP51-12 A TRAINING COURSE FOR THE UROLOGIST IMPROVES THEIR ABILITY TO INTERPRET CLINICALLY SIGNIFICANT PROSTATE CANCER ON MULTIPARAMETRIC MRI. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
143	PD43-06 A MULTIVARIATE LOGISTIC REGRESSION INVESTIGATING WHICH FACTORS INFLUENCE DETECTION OF CLINICALLY SIGNIFICANT CANCER BY MRI-TARGETED PROSTATE BIOPSY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
144	MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. <i>European Radiology</i> , 2017, 27, 4767-4774.	2.3	24

#	ARTICLE	IF	CITATIONS
145	The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPEDâ€”A Randomized, Placebo Controlled, Double-Blind Clinical Trial. <i>Journal of Urology</i> , 2017, 197, 1006-1013.	0.2	19
146	Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes. <i>BMJ Open</i> , 2017, 7, e017006.	0.8	35
147	A critical comparison of techniques for MRI-targeted biopsy of the prostate. <i>Translational Andrology and Urology</i> , 2017, 6, 432-443.	0.6	53
148	INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer. <i>BMC Cancer</i> , 2016, 16, 816.	1.1	40
149	Reorganising specialist cancer surgery for the twenty-first century: a mixed methods evaluation (RESPECT-21). <i>Implementation Science</i> , 2016, 11, 155.	2.5	18
150	Integrating MRI for the diagnosis of prostate cancer. <i>Current Opinion in Urology</i> , 2016, 26, 466-471.	0.9	5
151	MP53-03 TRANSPERINEAL MRI VISUALLY-TARGETED PROSTATE BIOPSIES COMPARED TO TEMPLATE MAPPING BIOPSY IN 534 MEN REQUIRING FURTHER RISK STRATIFICATION. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
152	Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation. <i>International Journal of Cancer</i> , 2016, 138, 1049-1057.	2.3	42
153	Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. <i>European Urology</i> , 2016, 70, 668-674.	0.9	56
154	Determination of optimal drug dose and light doseâ€”index to achieve minimally invasive focal ablation of localised prostate cancer using <sc>WST</sc>11â€”vascularâ€”targeted photodynamic (<sc>VTP</sc>) therapy. <i>BJU International</i> , 2015, 116, 888-896.	1.3	81
155	Will the attributes of multiparametric MRI permit the creation of a new approach to therapy?. <i>Current Opinion in Urology</i> , 2015, 25, 518-521.	0.9	2
156	A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance. <i>BMJ Open</i> , 2015, 5, e006674-e006674.	0.8	57
157	Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2015, 67, 627-636.	0.9	284
158	Focal Therapy: Patients, Interventions, and Outcomesâ€”A Report from a Consensus Meeting. <i>European Urology</i> , 2015, 67, 771-777.	0.9	206
159	A randomized controlled trial to investigate magnetic resonance imagingâ€”targeted biopsy as an alternative diagnostic strategy to transrectal ultrasoundâ€”guided prostate biopsy in the diagnosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 156-157.	0.8	0
160	The Evolution of Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2015, 68, 822-823.	0.9	4
161	Population-based prediction of subject-specific prostate deformation for MR-to-ultrasound image registration. <i>Medical Image Analysis</i> , 2015, 26, 332-344.	7.0	33
162	Focal Photodynamic Therapy. , 2015, , 163-178.		1

#	ARTICLE	IF	CITATIONS
163	Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis. <i>BMJ Open</i> , 2014, 4, e004895-e004895.	0.8	23
164	Can MRI replace serial biopsies in men on active surveillance for prostate cancer?. <i>Current Opinion in Urology</i> , 2014, 24, 280-287.	0.9	29
165	The PICTURE study â€” Prostate Imaging (multi-parametric MRI and Prostate HistoScanningâ„¢) Compared to Transperineal Ultrasound guided biopsy for significant prostate cancer Risk Evaluation. <i>Contemporary Clinical Trials</i> , 2014, 37, 69-83.	0.8	50
166	Role of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancer. <i>International Journal of Urology</i> , 2014, 21, 5-11.	0.5	11
167	Multiparametric Magnetic Resonance Imaging in the Management and Diagnosis of Prostate Cancer: Current Applications and Strategies. <i>Current Urology Reports</i> , 2014, 15, 390.	1.0	24
168	MRI-targeted prostate biopsy: a review of technique and results. <i>Nature Reviews Urology</i> , 2013, 10, 589-597.	1.9	43
169	Image-Guided Prostate Biopsy Using Magnetic Resonance Imagingâ€”Derived Targets: A Systematic Review. <i>European Urology</i> , 2013, 63, 125-140.	0.9	479
170	MAPPED study design: A 6month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging. <i>Contemporary Clinical Trials</i> , 2013, 34, 80-89.	0.8	22
171	Accuracy of <sc>HistoScanning</sc>â„¢ for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. <i>BJU International</i> , 2013, 111, 60-66.	1.3	28
172	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. <i>European Urology</i> , 2013, 64, 544-552.	0.9	383
173	Reply from Authors re: Hebert Alberto Vargas, Hedvig Hricak. Magnetic Resonance Imagingâ€”Targeted Prostate Biopsies: Now Is the Time to START. <i>Eur Urol</i> 2013;64:553â€”4. <i>European Urology</i> , 2013, 64, 555-556.	0.9	0
174	1466 COULD USE OF MRI IN MEN REFERRED FOR RISK OF PROSTATE CANCER RESULT IN A REDUCTION OF BIOPSY RELATED MORBIDITY WHEN COMPARED TO THE ERSPC AND PCPT RISK CALCULATORS FOR DECISION TO BIOPSY?. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
175	Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, 860-866.	0.2	181
176	<sc>TOOKAD</sc>â„® <sc>S</sc>oluble vascularâ€”targeted photodynamic (<sc>VTP</sc>) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. <i>BJU International</i> , 2013, 112, 766-774.	1.3	135
177	Multiparametric MR Imaging for Detection of Clinically Significant Prostate Cancer: A Validation Cohort Study with Transperineal Template Prostate Mapping as the Reference Standard. <i>Radiology</i> , 2013, 268, 761-769.	3.6	162
178	The role of MRI in active surveillance of prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 261-267.	0.9	28
179	Re: Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy Improves Cancer Detection Following Transrectal Ultrasound Biopsy and Correlates With Multiparametric Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2012, 187, 1511-1512.	0.2	3
180	The Accuracy of Different Biopsy Strategies for the Detection of Clinically Important Prostate Cancer: A Computer Simulation. <i>Journal of Urology</i> , 2012, 188, 974-980.	0.2	84

#	ARTICLE	IF	CITATIONS
181	Identifying Candidates for Active Surveillance: An Evaluation of the Repeat Biopsy Strategy for Men with Favorable Risk Prostate Cancer. <i>Journal of Urology</i> , 2012, 188, 762-768.	0.2	86
182	Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. <i>BJU International</i> , 2012, 109, 1636-1647.	1.3	103
183	Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning [®] . <i>BJU International</i> , 2012, 110, 28-35.	1.3	77
184	Re: A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial. <i>Journal of Urology</i> , 2011, 186, 1158-1159.	0.2	0
185	SURGICAL MANAGEMENT AFTER ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: PATHOLOGICAL OUTCOMES COMPARED WITH MEN UNDERGOING IMMEDIATE TREATMENT. <i>BJU International</i> , 2011, 107, 338-338.	1.3	3
186	Photodynamic therapy for prostate cancer-an emerging approach for organ-confined disease. <i>Lasers in Surgery and Medicine</i> , 2011, 43, 768-775.	1.1	28
187	Light penetration in the human prostate: a whole prostate clinical study at 763 nm. <i>Journal of Biomedical Optics</i> , 2011, 16, 015003.	1.4	19
188	THE EFFECTS OF THE TIME PERIOD BETWEEN BIOPSY AND DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING ON CANCER STAGING IN LOCALIZED PROSTATE CANCER. <i>BJU International</i> , 2010, 106, 131-132.	1.3	7
189	Photodynamic therapy for focal ablation of the prostate. <i>World Journal of Urology</i> , 2010, 28, 571-576.	1.2	52
190	Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. <i>BJU International</i> , 2010, 106, 991-997.	1.3	72
191	Focal Therapy in Prostate Cancer: Determinants of Success and Failure. <i>Journal of Endourology</i> , 2010, 24, 819-825.	1.1	22
192	Conceptual Basis for Focal Therapy in Prostate Cancer. <i>Journal of Endourology</i> , 2010, 24, 811-818.	1.1	27
193	Focal therapy for prostate cancer: Fact or fiction?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 550-556.	0.8	8
194	Time to evaluate focal therapy. <i>BMJ: British Medical Journal</i> , 2010, 340, c1057-c1057.	2.4	0
195	Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. <i>Surgical Oncology</i> , 2009, 18, 219-232.	0.8	90
196	Photodynamic therapy for prostate cancer—a review of current status and future promise. <i>Nature Reviews Urology</i> , 2009, 6, 18-30.	1.4	287
197	Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confined prostate cancer?. <i>BJU International</i> , 2005, 96, 754-758.	1.3	31